Membranous Nephropathy
Conditions
Interventions
experimental group:Rituximab 600mg iv, and supportive treatment
control group:Supportive treatment according to KDIGO guideline
Sponsors
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients who meet all of the following conditions will be introduced to this study: 1) age: 18 to 70 years old; 2) qualitative diagnosis: 24h urine protein more than 1 gram, anti-PLA2R antibody more than 50U/ml, and serum albumin more than 30g/L; 3) biopsy-proven or clinically diagnosed membranous nephropathy; 4) estimated GFR more than 30 ml/min; 5) patients and families are willing to participate in the study.
Exclusion criteria
Exclusion criteria: We exclude patients who have any of the following conditions: 1) tumor or expected survival period less than 6 months; 2) surgical procedure is needed recently; 3) pregnant or lactating women; 4) current bacterial infection; 5) latent tuberculosis, Hepatitis B or C virus infection, or any conditions infection physician consider not suitable for rituximab treatment; 6) active cytomegalovirus infection; 7) unexplained body temperature greater than 37.5 degrees celsius; 8) the researchers believe that there are other reasons not suitable for the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24 hour urine protein;Serum albumin;Serum Creatinine;anti PLA2R antibody;Judgment of Nephrotic Syndrome; | — |
Countries
China
Contacts
Public ContactGang Chen
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed